semaglutide · Novo Nordisk
What should I know about Semaglutide?
Semaglutide by Novo Nordisk: The molecule behind Ozempic, Wegovy and Rybelsus. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Alternatives
Berberine vs Ozempic: What the Evidence Actually ShowsNo — berberine is not "nature's Ozempic." Pooled trials show under 2 lbs of weight loss, while semaglutide produced 13.7% (33.1 lbs) at 72 weeks in a phase 3 trial. Berberine works through a different pathway and is not FDA-approved.Contrave vs. Wegovy: Weight Loss, Safety, Cost, and Who Fits EachContrave produced a placebo-subtracted mean weight loss of 4.7% at one year in its phase 3 trials, while Wegovy produced an average 13.7% loss at 72 weeks in SURMOUNT-5. The two differ sharply in safety profile, dosing, and price.Metformin for Weight Loss: How Much Can You Really Lose vs GLP-1s?Metformin produced an average 2.1 kg weight loss in the Diabetes Prevention Program, where body weight fell 2.06% with metformin vs 0.02% with placebo. Wegovy (semaglutide) delivered 13.7% and Zepbound (tirzepatide, a dual GIP/GLP-1) 20.2% at 72 weeks. Metformin is not FDA-approved for weight loss.Phentermine vs GLP-1 Drugs: Cost, Weight Loss, and Who Fits WhichPhentermine is a short-term oral appetite suppressant that averaged $15 out of pocket per 30-day fill in 2025, while GLP-1s like Wegovy and Zepbound cost far more — in a 72-week head-to-head trial, Wegovy produced 13.7% and Zepbound 20.2% average weight loss. Here is how they compare.
Results
Best Foods to Eat on GLP-1 Medications (and the Ones That Cause Trouble)There is no official GLP-1 diet, but because these drugs cut food intake sharply (35% lower in one trial), dietitians point to protein at every meal, fiber, and fluids, while fried, sugary, and fatty foods can worsen side effects. Here is what the labels, trials, and dietitians actually say.Exercise on GLP-1 Drugs: What the Evidence Actually ShowsGLP-1 drugs produce major weight loss without supervised exercise, but roughly 25-39% of the weight lost is lean mass, versus 17.5% when lifestyle programs include resistance training. Exercise's clearest benefits show up in body composition and keeping weight off after the drug stops.GLP-1 Meal Plan Principles: What to Eat on Semaglutide or TirzepatideClinical reviews and dietitians give GLP-1 users the same core advice: smaller, more frequent meals with 20 to 30 grams of protein per meal, scheduled fluids, and gradual fiber, because 40% to 70% of patients get GI side effects. Here is what the guidance says, and what 'GLP-1 friendly' on a package means.GLP-1 Plateau: Why Weight Loss Stalls on Wegovy and ZepboundYes — a stall is a normal part of treatment. In tirzepatide trials, the median time to a weight plateau was 24.3 to 36.1 weeks depending on starting BMI, and about 90% of participants had plateaued by week 72.How Fast Does Semaglutide Work? Trial Results by WeekSemaglutide weight-loss results come from fixed trial checkpoints: an average -10.6% at week 20, -14.9% at week 68, and a plateau near week 60. The 2.4 mg dose is reached at week 16, and appetite effects were measured at week 20, with lunch intake 35% lower than placebo.How Much Protein on a GLP-1: What Published Targets SayPublished sources suggest roughly 1.0–1.5 g of protein per kg of body weight per day, or 80–120 g total, for adults losing weight on semaglutide or tirzepatide, with about 20–30 g per meal plus resistance training to help preserve muscle.
Side effects
Can You Drink Alcohol on Semaglutide? What Labels and Trials SayThe Ozempic and Wegovy labels list contraindications for MTC/MEN 2 and hypersensitivity, and interactions with insulin and oral drugs. In a 26-week trial, semaglutide cut heavy drinking days by 41.1 vs 26.4 percentage points.Does Semaglutide Cause Muscle Loss?Some of the weight lost on semaglutide is lean tissue, which is true of nearly all weight loss, but the size of that share and what changes it are the parts worth understanding.How to Stop Nausea from Semaglutide: Timing, Diet, and Warning SignsNausea on semaglutide is common, peaks during the first 4 to 5 weeks and during dose escalation, and usually resolves within 8 days. Slower eating, smaller low-fat meals, and small sips of fluid help; a prescriber can slow the dose schedule if needed.Ozempic Face: What It Is, Why It Happens, and What You Can DoOzempic face is a colloquial term for the sunken, aged look that can follow rapid weight loss on semaglutide. It is not a medically recognized condition and poses no serious health risk, but options like fillers, skin-tightening procedures, and surgery can address the volume loss.Semaglutide and Surgery: Anesthesia Risk and What to Tell Your TeamSemaglutide slows stomach emptying, so food can remain even after fasting. A 2024 multi-society guidance says most patients continue the drug before elective procedures; the FDA label says data are insufficient to recommend stopping, and patients should tell providers about planned procedures.Semaglutide Side Effects: Complete List of Common and Serious ReactionsThe most common semaglutide side effects are digestive: nausea affected 44% of adults on Wegovy 2.4 mg versus 16% on placebo. Serious risks include pancreatitis, gallbladder disease, kidney injury, and a rare eye condition called NAION.Tirzepatide vs Semaglutide Side Effects: What Direct Comparison ShowsSURMOUNT-5 (751 adults) found mostly mild-to-moderate GI side effects in both arms; a 46,620-pair real-world study found an HR of 1.07 for serious GI events with tirzepatide vs semaglutide. Label percentages cannot be compared across drugs.
Stopping and switching
Coming Off Compounded Semaglutide: What to Do When Your Program EndsThe FDA resolved the semaglutide shortage on February 21, 2025, and the shortage-based window that let pharmacies compound copies closed by May 22, 2025. Here is what that means for your program ending and how to move to an FDA-approved drug.Do You Have to Take Wegovy Forever? What the Evidence ShowsWegovy's label sets no stop date and obesity guidance strongly recommends continuing medication during weight maintenance. In withdrawal trials, people who stopped regained most of their lost weight within a year, while those who continued kept it off.GLP-1 Maintenance Dose: What the Research Says About Lowering ItYes, labels allow lower maintenance doses, and a 112-week trial found tirzepatide 5 mg kept weight loss at -16.6% versus -9.9% on placebo. Spacing doses out has weaker evidence: one 30-person case series and computer models.What Happens When You Stop Taking a GLP-1?Stopping a GLP-1 usually leads to substantial weight regain within a year. In a pooled analysis of 8,993 adults across 6 studies, the difference in percent body-weight change between people who stopped and people who continued averaged 17.90%.
Compounded
Compounded Semaglutide vs Wegovy: Real Costs and Real TradeoffsCompounded semaglutide can still cost less upfront — one platform lists it starting at $60 plus a membership — but branded Wegovy self-pay is now $349 a month, or $199 for a new patient's first two fills. The gap has narrowed, and the compounded version skips FDA review entirely.Compounded Semaglutide: What It Is and Is It Safe?Compounded semaglutide is made by a compounding pharmacy and is not FDA approved, so it is not reviewed for safety, effectiveness or quality before sale. The FDA has received 990 adverse event reports for it as of May 31, 2026, plus overdose reports tied to dosing errors.How to Get Semaglutide Online: The Process and the Red FlagsGetting semaglutide online usually means an intake form, a clinician review, and a prescription routed to a pharmacy. Most states do not accept a questionnaire alone, LillyDirect-listed visits run $25/visit to $149/month excluding medication, and some services sell compounded drugs that are not FDA-approved.Is Compounded Semaglutide Legal in 2026? What the FDA Rules SayCompounded semaglutide is not banned by name, but mass compounding of copies ended after FDA resolved the shortage on February 21, 2025. Enforcement-discretion windows closed April 22, 2025 (503A) and May 22, 2025 (503B), and FDA now says semaglutide is on neither the shortage list nor the 503B bulks list.What Happened to Hims Semaglutide? The Full TimelineHims & Hers sold compounded semaglutide for $199 a month starting May 2024, but the FDA ended the semaglutide shortage in February 2025, cutting off mass compounding by May 22, 2025. A brief Novo Nordisk deal collapsed, an FDA warning letter followed, and the company now sells branded GLP-1 drugs.
FDA and regulation
FDA Approval History of Semaglutide: Every Date, ExplainedSemaglutide was first approved as Ozempic on December 5, 2017, followed by Rybelsus (September 20, 2019), Wegovy (June 4, 2021), Wegovy tablets (December 22, 2025) and Wegovy HD (March 19, 2026). Here is each approval, use, and how to verify the dates yourself.Is Compounded Semaglutide FDA Approved? Legal Status and Risks in 2026No. Compounded semaglutide is not FDA approved and never has been. The shortage-based pathway that let pharmacies compound it closed in 2025, courts upheld the FDA in August 2026, and only narrow patient-specific exceptions remain.Is Semaglutide Still in Shortage? FDA Status for 2026No. FDA declared the semaglutide injection shortage resolved on February 21, 2025, and an FDA statement dated April 1, 2026 confirms Ozempic and Wegovy are off the drug shortage list. Local pharmacy stock-outs can still happen.Semaglutide Approvals by Country: Where Ozempic and Wegovy Are ApprovedOzempic is approved in the US, EU, UK, Canada, Australia, Japan and China; Wegovy also in India and the UAE. Approved uses and dates differ by market. Canada approved the first G7 generic semaglutide on 28 April 2026 after a patent lapsed over an unpaid CAD 250 fee; US exclusivity runs to 2032.
Foundayo
Foundayo Results: What the Clinical Trials Actually ShowIn the 72-week ATTAIN-1 trial, people on the highest dose of Foundayo (orforglipron) lost an average of 12.4% of body weight (27.3 lbs) by the efficacy estimand, versus 0.9% on placebo. Lower figures like 11.2% come from the treatment-regimen estimand, not a different result.Foundayo vs Wegovy Pill: How the Two Oral GLP-1s CompareFoundayo (orforglipron) and the Wegovy pill (oral semaglutide 25 mg) are both once-daily weight-loss tablets, but no head-to-head weight trial exists. The key differences are dosing rules, approved uses, and cost.
Who they're for
GLP-1 After Bariatric Surgery: Does It Work for Weight Regain?Yes — the evidence says it can work. In a 68-week randomized trial, semaglutide 2.4 mg once weekly produced −18.0% body weight versus +0.4% on placebo in people with poor results after gastric bypass or sleeve, with no new safety concerns. No GLP-1 is FDA-approved specifically for post-bariatric use.GLP-1 and Men's Health: Testosterone, Erections, Sperm and MusclePost hoc analyses reported in a conference abstract suggest women lose about 40% more weight than men on GLP-1 drugs. A review of five trials found no negative impact on hormones, sexual function or sperm quality, with possible testosterone gains for men whose low T is driven by obesity [1][10].GLP-1 and Menopause: Weight Loss Evidence and Hormone Therapy EffectsGLP-1 drugs still produce strong weight loss after menopause: tirzepatide cut body weight 23% vs 3% placebo in postmenopausal women, and the STEP pool showed a median −16.4% for semaglutide. Hormone therapy is linked to more loss (16% vs 12% at 12 months), but no trial proves it causes the difference.GLP-1 for Teens: Which Drugs Are Approved and What Studies ShowOnly Wegovy injection (ages 12+) and Saxenda (ages 12+ with body weight over 60 kg) carry a teen weight-loss indication. Mounjaro is labeled for ages 10 and older only for type 2 diabetes, not weight loss. Zepbound is adults-only.GLP-1 for Type 1 Diabetes: What the Research Actually ShowsNo GLP-1 drug is FDA-approved for type 1 diabetes. One small randomized trial found 36% of adults on semaglutide hit a combined glucose-and-weight goal versus 0% on placebo, with weight 8.8 kg lower than placebo at 26 weeks.GLP-1 Over 65: What the Labels, Trials and Medicare Rules ShowNo GLP-1 label sets an upper age limit, and pooled trials find efficacy and safety in adults 65 and older broadly comparable to younger adults, though side effects force stopping more often after 65. Medicare's GLP-1 Bridge covers certain drugs for $50 a month from July 1, 2026 through December 31, 2027.Who Should Not Take GLP-1 Drugs: Contraindications and WarningsOnly two things rule out these drugs outright: a personal or family history of medullary thyroid carcinoma or MEN 2, and hypersensitivity to the drug or its ingredients (Wegovy's label says "known" hypersensitivity; the other three say "serious"). Everything else is a warning or "not recommended."
News timeline
GLP-1 News 2025: Stories That Changed Prices, Access and ApprovalsIn 2025, the FDA ended the semaglutide shortage, cash prices fell from a $1,349 list price to $499, Medicare obesity coverage and a $245 government price were set for 2026, and semaglutide gained kidney, liver and oral weight-loss approvals.History of Ozempic and Semaglutide: Year-by-Year Timeline of ApprovalsOzempic was FDA approved on December 5, 2017 for type 2 diabetes, followed by Rybelsus (September 20, 2019), Wegovy (June 4, 2021) and the Wegovy pill (December 22, 2025). Here is the full year-by-year history of semaglutide.
How it works
How Does Semaglutide Work in the Body?Semaglutide is a lab-made copy of the gut hormone GLP-1 that binds GLP-1 receptors to stimulate insulin, lower glucagon, slow stomach emptying, and reduce appetite in the brain. Three chemical changes give it a half-life of about one week, so one injection lasts seven days.How Does Zepbound Work? GIP and GLP-1, Explained SimplyZepbound (tirzepatide) activates two gut-hormone receptors at once, GIP and GLP-1, which is why it is called a dual agonist. It starts at 2.5 mg once weekly for 4 weeks and can go up to a 15 mg weekly maintenance dose.How Long Does Semaglutide Stay in Your System?Semaglutide has an elimination half-life of approximately 1 week, so it remains in circulation about 5 weeks after the last Ozempic dose and 5 to 7 weeks after the last Wegovy 2.4 mg dose. Here is what that means for starting, stopping, pregnancy planning, and surgery.Oral Semaglutide vs Injection: Pills, Pens, and What Actually DiffersOral semaglutide (Rybelsus, Ozempic, Wegovy tablets) and injectable semaglutide (Ozempic, Wegovy) are the same molecule with different rules: pills are daily on an empty stomach with a 30-minute wait; shots are weekly with no food limits. OASIS 4: the 25 mg pill gave −13.6% weight loss vs −2.2% placebo.Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide (Mounjaro) targets two. In the only head-to-head trial, tirzepatide produced −20.2% body weight vs −13.7% for semaglutide at 72 weeks.Who Discovered GLP-1? The People Behind Ozempic and WegovyNo single person discovered GLP-1. The work spans more than 30 years across several labs, and the 2024 Lasker Prize went to Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen. Ozempic is not made from Gila monster venom — that was exenatide, approved in 2005.
Cost
How Much Does Semaglutide Cost Without Insurance in 2026?Without insurance, brand-name semaglutide now runs about $149 to $499 a month depending on which product and dose you take, far below the $1,027 to $1,349 list prices.The Cheapest Way to Get Semaglutide: Every Legal Route and PriceThe cheapest legal route is Novo Nordisk's Patient Assistance Program, which supplies medicine free to approved applicants with Medicare or no insurance. Medicare's GLP-1 Bridge runs $50 a month. With commercial insurance, the savings offer is $25 a month for up to 3 months; cash prices start at $149.When Will Generic Semaglutide Be Available in the US?Generic semaglutide is not expected in US pharmacies until 2032, with patent loss in Europe and the US placed in the 2031–32 window. India lost protection in March 2026 and generics are on sale there now; Canada and Brazil have approved products, with launches pending.
Trial evidence
How Much Weight Do You Lose on Semaglutide? Results by Dose and TypeIn the STEP 1 trial, adults taking 2.4 mg semaglutide weekly lost an average of 14.9% of body weight (15.3 kg, about 34 lb) over 68 weeks, versus 2.4% on placebo. Results vary by dose, pill versus injection, and the population studied.SELECT Trial Semaglutide Explained: Heart Attack and Stroke ResultsSELECT tested 2.4 mg weekly semaglutide against placebo in 17,604 adults with overweight or obesity and existing heart disease but no diabetes. It cut major cardiovascular events 20% relative — 6.5% vs 8.0% — over about 3.3 years.Semaglutide Results Week by Week: What the Trials Actually ShowThere is no true week-by-week semaglutide chart from trials — results were reported at week 68 (−14.9%), week 104 (−15.2%) and week 208 (−10.2%). Here is what the data do show about the shape of the curve, side effects and plateaus.Semaglutide vs Tirzepatide: Which Is Better for Weight Loss? SURMOUNT-5 ExplainedIn the first published head-to-head randomized trial in adults with obesity without diabetes, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. Here is what the study showed, plus side effects, heart evidence, and how clinicians say to choose.What Happens When You Stop Taking Semaglutide (Ozempic, Wegovy)Yes — across randomized trials, people who stopped semaglutide or tirzepatide regained an average of 9.69 kg, and in one tirzepatide withdrawal trial the group switched to placebo regained 14.0% of body weight in a year.What Semaglutide Clinical Trial Results Actually ShowAcross the main trials, semaglutide produced 14.9% mean weight loss over 68 weeks without diabetes, cut HbA1c by 1.45–1.55% at 30 weeks, and lowered major cardiovascular events (HR 0.86 in SOUL). Main harms: gastrointestinal events and a retinopathy-complication signal (HR 1.76) in SUSTAIN 6.
Medications
How to Store an Ozempic Pen, Inject It, and Throw It Away SafelyUnused Wegovy pens stay in the fridge at 36 °F to 46 °F and can sit out at 46 °F to 86 °F for up to 28 days before the cap comes off. Ozempic storage limits are in section 16 of its prescribing information. Inject once weekly into the abdomen, thigh, or upper arm, and throw used pens in a sharps container.Ozempic vs Wegovy vs Rybelsus: What Actually DiffersOzempic, Wegovy and Rybelsus all contain semaglutide, but they differ in approved uses, doses, shot vs pill, and price. The reformulated Rybelsus tablets were renamed Ozempic tablets on January 30, 2026, and the Rybelsus name is being retired in the US as the Ozempic pill rolls out from May 4, 2026.Switching GLP-1 Medications: What the Labels and Guidelines SayNo dose-conversion chart between different GLP-1 molecules appears in the FDA labels reviewed here. In these labels, switching instructions appear only within the semaglutide family and before starting fixed-ratio insulin combos. Up to one-fourth of patients switch off their first GLP-1 after year one.Trulicity vs Ozempic: Which Works Better, Dosage, and CostTrulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 injections for type 2 diabetes, and the retrieved labeling lists no weight-loss use for either. Trulicity lists at $1,006.93 per month; the Ozempic pill self-pays at $149 to $299 per month.
How to use
How to Take GLP-1 Pills Correctly: Wegovy Tablets vs. FoundayoOral semaglutide (Wegovy tablets) is taken once daily on an empty stomach in the morning with up to 4 ounces of water, then wait at least 30 minutes before food, drink, or other medicines. Foundayo is one tablet a day, any time, with or without food.Missed Dose of Ozempic or Another GLP-1: What the Labels SayEach GLP-1 product has its own missed-dose rule. The Ozempic label allows the shot within 5 days of the missed dose; Wegovy injection depends on whether the next dose is more or less than 2 days (48 hours) away; Mounjaro and Zepbound allow 4 days (96 hours).Semaglutide Units to mg Calculator Math: How the Conversion WorksOn a U-100 insulin syringe, 100 units equals 1 mL, so units = (mg × 100) ÷ the concentration printed on your vial. The same 0.25 mg dose can be 5 units or 12.5 units depending on that concentration.
Liraglutide
Liraglutide FAQ: Victoza, Saxenda, Generics, Doses and CostsLiraglutide is a once-daily GLP-1 injection sold as Victoza for type 2 diabetes and Saxenda for weight loss, with generics now on the market. Generic liraglutide runs about $112.19 for a 2-pen Victoza-style carton or $372.45 for a 5-pen Saxenda-style carton with a GoodRx coupon.Saxenda vs Wegovy: Which Works Better and How They DifferIn the 68-week STEP 8 trial, weekly semaglutide 2.4 mg produced −15.8% mean weight loss vs −6.4% for daily liraglutide 3.0 mg — a 9.4-point gap. Generic liraglutide launched in August 2025; a GoodRx coupon listed $372.45 for one 5-pen carton (ZIP 33102, September 14, 2026).Switching From Liraglutide to Semaglutide or Zepbound: Doses and GapsNone of the Wegovy, Zepbound, oral semaglutide, or Saxenda labels offers a liraglutide-to-weekly-drug conversion. Wegovy starts at 0.25 mg once weekly for 4 weeks and Zepbound at 2.5 mg once weekly for 4 weeks, and no washout period appears in these labels.Victoza vs Ozempic: Which Is Better for Type 2 Diabetes?Victoza (liraglutide) is a once-daily injection with a cheaper generic; Ozempic (semaglutide) is once weekly and lowered A1C more in the SUSTAIN 10 head-to-head trial (−1.7% vs −1.0% at 30 weeks). Here is how the two compare on weight, side effects, heart risk, and cost.
Drug pipeline
Mazdutide: Weight-Loss Results, Approval Status, and US AvailabilityMazdutide is a dual glucagon/GLP-1 drug approved in China for weight management and type 2 diabetes, not by the FDA. In the Phase 3 GLORY-2 study, the 9 mg dose produced 18.55% mean weight loss over 60 weeks versus 3.02% for placebo.When Will Generic Ozempic Be Available in the US?No FDA-approved generic Ozempic exists as of August 2026, and experts do not expect one in the US until at least the end of 2031. India and Canada already have approved generics; the advocacy group I-MAK projects US patents could block entry as far out as 2042.
Emerging uses
Microdosing Semaglutide: What It Means, Whether It Works, and Safety"Microdosing" semaglutide means taking doses below what the FDA approved and studied, often without medical supervision. There is no official definition or dose, no robust clinical evidence it works, and weight loss at very low doses tends to be modest, around 5% to 6%.Ozempic Babies: Why Unexpected Pregnancies Happen on GLP-1s"Ozempic babies" are unexpected pregnancies in people taking GLP-1 drugs, mostly because weight loss restores ovulation. Semaglutide has not been shown to weaken the pill, but tirzepatide cut pill hormone levels by up to 66%, and the Wegovy label says to stop at least 2 months before a planned pregnancy.Semaglutide Alzheimer's Trial Results: What EVOKE ShowedNo. In two phase 3 trials of 3,808 people with early Alzheimer's, oral semaglutide did not slow disease progression on the primary CDR-SB endpoint or any secondary measure, though some biomarkers improved. Topline results were announced 24 November 2025.Semaglutide and Alcohol Cravings: What the Research ShowsYes—early trial evidence points that way. Three small randomized trials report fewer heavy drinking days on semaglutide, including a 41.1% drop in one 26-week trial, though craving results are mixed. It is not FDA-approved for alcohol use disorder, and larger trials are still needed.Semaglutide for PCOS: What the Research Actually ShowsSemaglutide is not FDA-approved for PCOS. Two small Chinese trials found adding it to metformin improved weight loss and menstrual-cycle recovery versus metformin alone; one reported a 35% vs. 15% natural pregnancy rate. Prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025.What Else Can Semaglutide Treat Besides Weight Loss?FDA-approved semaglutide uses go beyond weight loss: type 2 diabetes, cardiovascular risk reduction, chronic kidney disease (Ozempic, added January 28, 2025), and fatty liver disease (Wegovy, August 15, 2025). Heart failure, sleep apnea, and Alzheimer's are not approved uses.What Else Can Tirzepatide Treat? Approved and Studied UsesTirzepatide (Mounjaro, Zepbound) is FDA-approved for type 2 diabetes, weight loss, sleep apnea, and — since August 2026 — reducing heart attack and stroke risk in adults with diabetes at high risk. Heart failure, diabetes prevention, and fatty liver show positive trials but no approval.
Common questions
The GLP-1 market
Recent Semaglutide news
Full timeline- Research and trials
Vanda's tradipitant cut Wegovy-induced vomiting by 27% in Phase 3 trial